TCB and its subsidiary TSP, have established world-class target identification and validation capabilities. Together they have developed a promising pipeline of novel drug discovery targets and compounds in key areas of unmet medical need such as CNS disorders, chronic pain and urology indications, endocrinology and metabolic-related diseases.
The acquisition by Takeda of TCB and its subsidiary TSP in March 2007 enabled Takeda to add research bases equipped with the state-of-the-art technologies in both the UK & Singapore. Formerly Paradigm Therapeutics, TCB was founded in 1999 by Cambridge University researchers and incorporated TSP in 2003. By using genetic models and in vivo pharmacology TCB has developed a promising pipeline of novel drug discovery projects that complement programmed and precedented targets.
Mark Carlton, PhD - President and Chief Scientific Officer
Ian Gray, PhD - Vice President, Research, Singapore
Jim Sutcliffe - Group Financial Controller
Founded in 1781 and located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. Takeda markets a number of blockbuster drugs discovered through its internal research programmes including Actos®, Blopress®, and Prevacid ®. Takeda Worldwide